Welcome to our dedicated page for PACS Group SEC filings (Ticker: PACS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. director and executive officer Mark Hancock reported a bona fide gift transfer of 300,000 shares of common stock on March 5, 2026. The shares were gifted to a charitable donor-advised fund and carried a reported price of $0.00 per share. After this disposition, Hancock directly owned 54,504,443 shares of PACS Group common stock.
PACS Group, Inc. reported that director Patrick Hugh Conway acquired 3,497 restricted stock units (RSUs) of Common Stock as a grant. Each RSU represents the right to receive one share of Common Stock upon vesting. According to the terms, 100% of the RSUs will vest on the earlier of March 4, 2027 or the next annual meeting following the grant date, subject to his continued service to the company.
PACS Group, Inc. filed an initial insider ownership report for Patrick Hugh Conway, who is identified as a director of the company. This Form 3 filing establishes his status as a reporting person for future insider ownership and trading disclosures. The filing does not list any specific transactions.
PACS Group, Inc. has appointed Patrick H. Conway, MD, MSc, to its Board of Directors as a Class III director, with a term running until the 2027 annual stockholders’ meeting. He will receive the standard non-employee director compensation and sign the company’s usual indemnification agreement.
Dr. Conway is CEO of Optum, the health services business of UnitedHealth Group, and a former senior leader at the Centers for Medicare and Medicaid Services, where he helped drive the shift toward value-based care. The company highlights his clinical background as a practicing pediatric hospitalist and his national recognition for healthcare leadership.
The filing also notes that PACS operates more than 320 post-acute care facilities across 17 states, serves over 31,700 patients daily, and reported full-year 2025 revenue of $5.29 billion, a 29.3% year-over-year increase, underscoring its scale and recent growth in the skilled nursing sector.
PACS Group, Inc. reported that Chief Compliance Officer Kelly Priegnitz received an award of 30,000 shares of common stock in the form of restricted stock units. Each RSU converts into one share upon vesting. The RSUs vest in substantially equal annual installments on the first, second, and third anniversaries of December 1, 2025, contingent on continued service.
PACS Group, Inc. reported that Chief Human Resources Officer Trent Dean Bingham received a grant of 25,000 shares of Common Stock in the form of restricted stock units. Each RSU converts into one share upon vesting, in substantially equal annual installments on the first, second, and third anniversaries of November 10, 2025, contingent on continued service.
PACS Group, Inc. filed an initial ownership report on Form 3 for Kelly Priegnitz, who serves as Chief Compliance Officer. The filing establishes her status as an officer subject to insider reporting rules but does not list any specific transactions or share amounts.
PACS Group, Inc. executive Bingham Trent Dean, the company’s Chief Human Resources Officer, has filed an initial Form 3 reporting his status as an officer of the company. The filing does not report any insider buy, sell, acquisition, or disposal transactions in PACS Group stock.
PACS Group, Inc. reports strong full-year 2025 results as a leading U.S. post-acute and skilled nursing operator. The company generated
PACS operates 321 post-acute care facilities across 17 states, serving over 31,700 patients daily, and focuses on transforming underperforming nursing homes into higher-acuity, short-term transitional care centers. Mature facilities posted an average QM Star rating of 4.4 and 95% occupancy, exceeding industry averages.
The business is highly dependent on Medicare and Medicaid, which supplied 33.7% and 40.5% of routine revenue in 2025, and carries